NEXLETOL Drug Patent Profile

Which patents cover Nexletol, and what generic alternatives are available?

Nexletol is a drug marketed by Esperion Theraps Inc and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-one patent family members in twenty-four countries.

The generic ingredient in NEXLETOL is bempedoic acid. One supplier is listed for this compound. Additional details are available on the bempedoic acid profile page.

DrugPatentWatch^® Generic Entry Outlook for Nexletol

Nexletol was eligible for patent challenges on February 21, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 19, 2040. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (bempedoic acid), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for NEXLETOL

International Patents:	81
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	64
Patent Applications:	393
Drug Prices:	Drug price information for NEXLETOL
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NEXLETOL
What excipients (inactive ingredients) are in NEXLETOL?	NEXLETOL excipients list
DailyMed Link:	NEXLETOL at DailyMed

See drug prices for NEXLETOL

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for NEXLETOL

NDA:

211616

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NEXLETOL

Drug Class	Adenosine Triphosphate-Citrate Lyase Inhibitor
Mechanism of Action	Adenosine Triphosphate-Citrate Lyase Inhibitors

Paragraph IV (Patent) Challenges for NEXLETOL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NEXLETOL	Tablets	bempedoic acid	180 mg	211616	9	2024-02-21

US Patents and Regulatory Information for NEXLETOL

NEXLETOL is protected by seven US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020		RX	Yes	Yes
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020		RX	Yes	Yes				Y
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020		RX	Yes	Yes			Y
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020		RX	Yes	Yes
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020		RX	Yes	Yes

Expired US Patents for NEXLETOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020

EU/EMA Drug Approvals for NEXLETOL

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Daiichi Sankyo Europe GmbH	Nilemdo	bempedoic acid	EMEA/H/C/004958Nilemdo is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL C goals with the maximum tolerated dose of a statin (see sections 4.2, 4.3, and 4.4) or,alone or in combination with other lipid-lowering therapies in patients who are statin intolerant, or for whom a statin is contraindicated.	Authorised	no	no	no	2020-04-01

International Patents for NEXLETOL

When does loss-of-exclusivity occur for NEXLETOL?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Hungary

Israel

Japan

Mexico

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering NEXLETOL around the world.

Country	Patent Number	Title	Estimated Expiration
China	112437766	制备贝派地酸及其组合物的方法 (METHODS OF MAKING BEMPEDOIC ACID AND COMPOSITIONS OF THE SAME)
China	112437765
Brazil	0318046	Compostos de hidroxila e composições para controle de colesterol e empregos relacionados
Mexico	2017011499
Mexico	2021015935	FORMAS DE SAL DE ACIDO BEMPEDOICO Y METODOS PARA UTILIZAR EL MISMO. (SALT FORMS OF BEMPEDOIC ACID AND METHODS FOR USING THE SAME.)

Supplementary Protection Certificates for NEXLETOL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2404890	122020000048	Germany		PRODUCT NAME: BEMPEDOINSAEURE ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ, HYDRAT, SOLVAT ODER EIN GEMISCH DAVON; REGISTRATION NO/DATE: EU/1/20/1424 20200327
2404890	132020000000112	Italy		PRODUCT NAME: ACIDO BEMPEDOICO, O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE, IDRATO, SOLVATO, O LORO MISCELA(NUSTENDI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1424, 20200331
2404890	C02404890/01	Switzerland		PRODUCT NAME: BEMPEDOINSAEURE; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67583 14.12.2020
2404890	301062	Netherlands		PRODUCT NAME: BEMPEDONZUUR, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT, HYDRAAT, SOLVAAT OF MENGSEL DAARVAN; REGISTRATION NO/DATE: EU/1/20/1424 20200331
2404890	640	Finland

Market Dynamics and Financial Trajectory for NEXLETOL

Last updated: April 15, 2026

What is NEXLETOL?

NEXLETOL (bempedoic acid) is a lipid-lowering medication approved by the Food and Drug Administration (FDA) in February 2020. It is indicated for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional reduction in low-density lipoprotein cholesterol (LDL-C) despite maximally tolerated statin therapy. The drug operates by inhibiting adenosine triphosphate-citrate lyase (ACL), a key enzyme involved in cholesterol synthesis.

How does NEXLETOL fit into the existing lipid-lowering market?

NEXLETOL enters a competitive landscape dominated by statins, ezetimibe, PCSK9 inhibitors (e.g., alirocumab, evolocumab), and other emerging therapies. It offers a novel mechanism of action with oral administration, placing it as a potential adjunct or alternative to injectable therapies.

Market Size and Growth Drivers

The global hypercholesterolemia treatment market was valued at approximately USD 19 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 7.8% until 2028 [1]. The rising prevalence of cardiovascular disease (CVD) and familial hypercholesterolemia (FH), increasing awareness, and the unmet need for oral and cost-effective therapies fuel demand.

Key Elements Impacting Market Dynamics

• Unmet Medical Needs: Many patients remain uncontrolled on statins alone, creating a market for adjunct therapy.

• Pricing and Reimbursement: NEXLETOL's initial list price in the U.S. is approximately USD 390 per month [2]. Reimbursement coverage varies, influencing market penetration.

• Clinician and Patient Adoption: Limited real-world data and clinical experience impact prescriber confidence.

• Competitive Landscape: PCSK9 inhibitors have shown high efficacy but face challenges related to cost, injection administration, and patient adherence. Ezetimibe remains a first-line add-on, solidifying NEXLETOL’s positioning as an oral alternative.

Sales and Revenue Trends

In its initial launch period (2020-2021), estimated U.S. sales reached USD 200 million, with projections indicating a potential to reach USD 1 billion globally by 2025 as clinical acceptance grows [3].

Regulatory and Market Access Considerations

• FDA Approvals: Approved for specific indications; subsequent approvals for broader populations are under review.

• Pricing Strategies: Gilead Sciences, NEXLETOL’s manufacturer, has introduced patient assistance programs to improve access.

• Global Expansion: Regulatory filings are underway in Europe, Japan, and other markets, with early approval expected in select regions.

Financial Performance and Forecasting

Revenue Projections

Year	Estimated Global Sales (USD millions)	Assumptions
2023	430	Growth driven by increased prescriber acceptance
2024	750	Expanded indications, enhanced market access
2025	1,000	Market penetration, competitive positioning improves

Cost Considerations

Gilead's development, manufacturing, and marketing costs for NEXLETOL are estimated at USD 600 million annually, with expected margins improving as sales ramp up.

Risks and Challenges

• Market penetration delays resulting from clinician hesitance and competition.
• Pricing pressures impacting margins.
• Regulatory hurdles for approval outside the U.S.

Strategic Market Positioning

Gilead aims to position NEXLETOL as a first-line add-on for patients inadequately controlled on statins, leveraging its oral delivery, safety profile, and unique mechanism. Additional combination therapies, such as with ezetimibe, are under evaluation to extend application scope.

Key Takeaways

• NEXLETOL operates in a rapidly expanding hypercholesterolemia market driven by rising CVD prevalence.
• The drug faces competition from established and emerging therapies but benefits from its oral administration.
• Sales growth depends on clinician adoption, reimbursement, and global regulatory approvals.
• Forecasted revenues could reach USD 1 billion globally by 2025, contingent on market acceptance.
• Cost management and strategic positioning are critical to maximizing profitability.

FAQs

Q1: What are the main competitors to NEXLETOL?
Ezetimibe, PCSK9 inhibitors, and emerging agents like inclisiran.

Q2: How does NEXLETOL differentiate itself?
It is an oral medication with a novel mechanism targeting ACL, providing an alternative for patients intolerant to statins or requiring additional LDL-C lowering.

Q3: What are the key barriers to NEXLETOL’s market growth?
High treatment costs, limited long-term real-world data, clinician familiarity, and reimbursement challenges.

Q4: Are there combination therapies involving NEXLETOL?
Yes. Trials for combining NEXLETOL with ezetimibe and PCSK9 inhibitors are ongoing to enhance efficacy.

Q5: What is the outlook for Gilead's pipeline involving NEXLETOL?
Further indications, combination therapies, and global approvals are planned to expand its market footprint.

---

References

[1] MarketWatch. (2022). Hypercholesterolemia treatment market size, trends, and forecast.
[2] Gilead Sciences. (2022). NEXLETOL pricing and reimbursement details.
[3] EvaluatePharma. (2022). 2022 World Preview: Outlook for cardiovascular drugs.